In a preclinical model comparing ACTIFUSE Bone Graft Substitute to β-TCP at 3, 6 and 12 weeks, ACTIFUSE Bone Graft Substitute treated animals had greater new normalized bone volume than β-TCP treated animals.

*More bone, Less time*¹

*¹In a preclinical model comparing ACTIFUSE Bone Graft Substitute to β-TCP at 3, 6 and 12 weeks, ACTIFUSE Bone Graft Substitute treated animals had greater new normalized bone volume than β-TCP treated animals.
Actifuse products are designed to be used alone. They can be mixed with sterile saline/water, autologous blood or bone marrow aspirate at the discretion of the surgeon but this may affect handling.

**Actifuse Shape**

- **Irrigation Resistance**
  - Remains resistant to irrigation.*\(^5\)

- **Malleable Consistency**
  - Ensures the ability to address the unique contours of each defect.

**Actifuse MIS System**

- **Enhanced Control**
  - Ergonomic handle and specially engineered trigger enables one-handed delivery of a controlled amount of ACTIFUSE ABX.

- **Targeted Delivery**
  - Tip is designed to enable access to difficult to reach surgical sites.

---

**Comparison to Iliac Crest**

Actifuse Bone Graft Substitute has shown similar fusion rates in comparison to iliac crest in both a clinically relevant ovine PLF model*\(^3\) as well as in a retrospective human study (vs historical controls).*\(^4\)

---

**Comparison to BMP-2**

Actifuse Bone Graft Substitute was safe and well tolerated in patients with degenerative spinal disorders requiring posterolateral fusion (PLF) and provided fusion rates similar to BMP-2.*\(^2\)

---

*As demonstrated in an animal model. Results may not correlate to performance in humans.
Orthopedic Indication for ACTIFUSE Bone Graft Substitute

ACTIFUSE Bone Graft substitute is a bone void filler intended only for orthopedic applications as a filler for gaps and voids that are not intrinsic to the stability of the bony structure. ACTIFUSE Bone Graft substitute is indicated to be packed gently into bony voids or gaps of the skeletal system, i.e. extremities, pelvis and spine including use in posterolateral spinal fusion procedures with appropriate stabilizing hardware. These defects may be surgically created osseous defects or osseous defects created from traumatic injury to the bone. The product provides a bone void filler that resorbs and is replaced by bone during the healing process.

Important Risk Information for ACTIFUSE Bone Graft Substitute

ACTIFUSE Bone Graft substitute is contraindicated where the device is intended as structural/load-bearing support in the skeletal system. ACTIFUSE Bone Graft substitute has not been cleared for use in vertebroplasty.

Attempts should not be made to modify the size of the granules or to change their shape. It is important to maximize contact between existing bone and the implant to ensure proper bone regeneration.

The effect of mixing ACTIFUSE Bone Graft Substitute with substances other than sterile saline/water, autologous blood or bone marrow aspirate is unknown.

Rx Only. For safe and proper use please refer to full device Instructions for Use for Contraindications, Warnings, and Precautions.

For questions or ordering information, please contact your Baxter representative.
www.advancedsurgery.baxter.com

Advancing the art of healing

2. ACTIFUSE Bone Graft Substitute Instructions for Use.

Baxter, Actifuse and Actifuse logo are registered trademarks of Baxter International Inc., or its subsidiaries.
USMP/MG95/20-0008 7/2020